Furthermore, cancer stem cell migration in vitro was also reduced when treated with antiIL-6 antibodies or tocilizumab, and cultures had a smaller fraction of cancer stem cells, a key piece of data helping to further describe the contribution of cancer stem cells and IL-6 in tumorigenesis and metastatic spread [138,139]. This evidence concerns the gene IL6 and cancer.